Last reviewed · How we verify
NCT05198284
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
trial testing KidneyIntelX in Diabetic Kidney Disease in 2,000 participants. Participants enrolled and being followed up; not accepting new ones.
1 December 2023
Quick facts
| Lead sponsor | Renalytix AI, Inc. |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 November 2021 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- KidneyIntelX
Conditions studied
- Diabetic Kidney Disease — all drugs for Diabetic Kidney Disease →
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
- Chronic Kidney Disease Stage 1 — all drugs for Chronic Kidney Disease Stage 1 →
- Chronic Kidney Disease Stage 2 — all drugs for Chronic Kidney Disease Stage 2 →
Sponsor
Renalytix AI, Inc.
Who can join
23 and older, any sex, with Diabetic Kidney Disease or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05198284
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of KidneyIntelX
Trials testing the same drug.
- NCT04960514 — Prospective Decision Impact Trial of KidneyIntelX · active not recruiting
- NCT04791358 — Decision Impact Trial of KidneyIntelX · recruiting
- NCT04802395 — Real World Evidence Clinical Utility Study of KidneyIntelX · recruiting
Other recruiting trials for Diabetic Kidney Disease
Currently open trials in the same condition.
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT06666283 — A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients · Phase 1 · recruiting
- NCT07338435 — "Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)" · NA · active not recruiting
- NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
- NCT06532682 — Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes · Phase 4 · active not recruiting
Other Renalytix AI, Inc. trials
Trials by the same sponsor.
- NCT04960514 — Prospective Decision Impact Trial of KidneyIntelX · active not recruiting
- NCT04791358 — Decision Impact Trial of KidneyIntelX · recruiting
- NCT04802395 — Real World Evidence Clinical Utility Study of KidneyIntelX · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05198284 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renalytix AI, Inc.
- Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05198284.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing